Търсене на изпитвания

Активни:

Намерени 4,781 изпитвания Стр. 41 от 240

Набира участници Фаза 2/3

Study of the Efficacy and Safety of ICP-332 in Participants With Chronic Spontaneous Urticaria

Chronic Spontaneous Urticaria (CSU)

The purpose of this study is to compare the efficacy and safety of ICP-332 in moderate to severe chronic spontaneous urticaria subjects inadequately controlled by second generation H1-antihistamines

Начало: 13.02.2026 Край: 01.09.2028 Възраст: 18–75 г.

China Beijing InnoCare Pharma Tech Co., Ltd. NCT07378527

Набира участници

BrainLive Connect: Volunteer Training Programme

Healthy Adults Aged 50 and Over

The goal of this mixed method clinical trial is to evaluate whether BrainLive Coach training can enhance knowledge, skills, and wellbeing among young old volunteers. The main question it aims to answer are: • Do trained BrainLive Coaches demonstrate greater CST-related knowledge/skills, self-efficacy, and improved quality of life compared with volunteers receiving only educational materials? Researchers will compare the BrainLive Coach training group vs. general service group (young old volunteers) to see whether the intervention leads to enhanced dementia knowledge, sense of competence in dementia care, and approaches to dementia. Participants will be: 1. Adults aged 50 and over - volunteers (nRCT) * Participate in either 80-90 hours of BrainLive Coach training followed by volunteering in BrainLive Connect or receive educational materials on dementia and cognitive health. * Complete assessments at baseline (T0) and post intervention (T1) on dementia knowledge, competence in dementia care, self-efficacy, attitudes to dementia, quality of life, and social capital. 2. Qualitative study participants • Take part in individual interviews or focus groups, including trained volunteers, and NGO staff, to explore perceived impacts, mechanisms, implementation facilitators/barriers, and areas for improvement.

Начало: 13.02.2026 Край: 10.11.2027 Възраст: от 50 г.

Hong Kong The University of Hong Kong NCT07544875

Набира участници

Male Experiences With Intra Cytoplasmic Sperm Injection (ICSI) and Reduced Sperm Quality

Psychological Experience in Fertility Treatment Hypogonadism Testosteron Levels Quality of Life +2

Several international studies indicate that men with reduced semen quality often feel overlooked in the context of fertility treatment. Men who undergo fertility treatment due to their own infertility, exhibit increased concern and experience more negative emotions such as loss, stigmatization, and low self-esteem - more so than men undergoing fertility treatment for other reasons. Since 2008, there has been limited research on the experiences of male patients with infertility in Denmark. Furthermore, there is generally very little knowledge regarding the testosterone levels (hypogonadism) of male infertile patients and its association with quality of life. Thus, there is a lack of updated insight into how infertile men experience their situation today. Additionally, the present study finds it relevant to examine whether men's needs and experiences in interactions with health professionals have changed over the past 15 years.

Начало: 13.02.2026 Край: 15.01.2029 Възраст: от 18 г.

Denmark Peter Humaidan NCT07546435

Набира участници Фаза 1

Anti-Ly6E Exatecan ADC M7437 in Advanced Solid Tumors

Advanced Solid Tumors

The purpose of this first-in-human (FIH) study is to evaluate the safety, tolerability, Pharmacokinetics (PK), and preliminary clinical activity of M7437 in participants with locally advanced or metastatic solid tumors with known Ly6E expression, including non-small cell lung cancer (NSCLC), triple-negative breast cancer (TNBC), epithelial ovarian carcinoma (EOC), squamous cell carcinoma of the head and neck (SCCHN), pancreatic ductal adenocarcinoma (PDAC), and gastric cancer (GC).

Начало: 13.02.2026 Край: 28.03.2029 Възраст: от 18 г.

Canada, Japan, Spain +1 EMD Serono Research & Development Institute, Inc. NCT07360314

Набира участници Фаза 2

A Study of Brenipatide in Participants With Opioid Use Disorder

Opioid Use Disorder

The purpose of this study is to see if brenipatide, when compared to placebo, is safe and effective for participants with opioid use disorder, when used with buprenorphine with or without naloxone. The maximum potential duration of study participation for a participant in Part A is approximately 144 weeks, maximum potential duration of study participation for a participant in Part B is approximately 116 weeks. The actual duration will vary for each participant depending on the time of enrollment and the overall rate of study enrollment.

Начало: 13.02.2026 Край: 01.03.2028 Възраст: 18–75 г.

Canada, Puerto Rico, United Kingdom +1 Eli Lilly and Company NCT07420283

Набира участници

ROME GS System Study

Diabetes Diabetes Melletus, Type 1 Diabetes Mellitus, Type 2

The purpose of this clinical investigation is to demonstrate that the proposed physical changes to the ROME GS Sensor do not have any adverse impact on safety and performance when compared to the Eversense 365 Sensor.

Начало: 12.02.2026 Край: 01.12.2028 Възраст: от 18 г.

United States Senseonics, Inc. NCT07518004

Набира участници

Testing Implementation Strategies to Scale-up a Multicomponent Continuum of Service Intervention for Families Involved in Systems With Parental Opioid and Methamphetamine Use

Substance Related Disorders

This study will explore how to expand the Just Care for Families (JCFF) program beyond its current sites in Oregon, while addressing two main challenges: the developer team cannot provide ongoing support to every new program, and rural counties face limits on caseloads and reimbursement because of long travel distances. To overcome these barriers, the trial will test two strategies-using a JCFF mobile app to improve outcomes and efficiency, and relying on trained Experts (instead of the developer team) to guide new counties. With five active counties and four new ones, researchers will study whether parents receiving JCFF with digital support show reduced opioid and stimulant use, better child welfare outcomes like reunification, and more efficient treatment. This study will also compare how well new counties implement JCFF compared to existing ones, and use modeling to see if digital tools help programs sustain themselves by balancing caseloads and reimbursement. This study is supported by and included in the Helping to End Addiction Long-term Initiative (https://heal.nih.gov/).

Начало: 12.02.2026 Край: 31.05.2030

United States Chestnut Health Systems NCT07365293

Набира участници Фаза 2

A Study of D-2570 in Patients With Active Systemic Lupus Erythematosus (SLE)

Active Systemic Lupus Erythematosus

This study is a multicenter, randomized, double-blind, placebo-controlled Phase II clinical trial designed to evaluate the efficacy and safety of D-2570 in the treatment of active systemic lupus erythematosus.

Начало: 12.02.2026 Край: 31.12.2028 Възраст: 18–70 г.

China InventisBio Co., Ltd NCT07311200

Набира участници

Developing and Testing a Digital Health Tool for INterseCtional Stigma Assessment and Reduction at Multiple Levels and mUltiple DimEnsions (INCLUDE) to Improve HIV Care in ART Centers in Nepal

HIV Care Loss to Followup HIV Antiretroviral Therapy (ART) Adherence HIV Stigma Mental Health Conditions +4

People living with HIV (PLWH) have poor clinical outcomes when they are excluded from care due to intersectional stigma related to HIV, mental health (MH), and other dimensions. Recent studies and reviews have highlighted three major challenges in identifying and addressing intersectional stigma: a lack of stigma assessment strategies that are multi-dimensional and can be incorporated into routine clinical care, a lack of tailored stigma-reduction activities, and a lack of implementation of multi-level interventions. These gaps make it difficult to recognize and address intersectional stigma, leading to poor HIV care outcomes globally. Digital health tools, co-designed with PLWH and healthcare workers (HCWs), have the potential to assist ART centers in addressing these challenges. Guided by the principles of human-centered design, our team has developed a digital tool with three components that can address the challenges in assessing, prioritizing, and addressing intersectional stigma in ART centers. The components include: 1) a dynamic assessment strategy that can be used during a clinic visit to collect both quantitative (i.e., ratings) and qualitative data (i.e., free text of client's perspectives) on stigma reported by PLWH; 2) a dashboard that incorporates this stigma assessment data alongside routine clinical data (i.e., existing registry of clients in the ART center) so that ART centers can directly link stigma with care engagement, and also identify relevant stigma-reduction activities; and 3) a repository of evidence-based, culturally appropriate activities that can reduce stigma at the intrapersonal-, interpersonal-, and clinic-levels. The three components of the digital intervention are theoretically grounded and are based on prior studies and consultations with local partners. The study aims to assess the acceptability and feasibility of INCLUDE among clients, HCWs, and ART center leads in four ART centers. For this aim, we will conduct a pilot trial at four ART centers to assess the acceptability and feasibility of INCLUDE. If successful, this study will provide an intervention that can be incorporated into routine clinical practice to systematically identify and address intersectional stigma to improve HIV care, and can be tested in a cluster randomized trial with ART centers in Nepal and other regions that face similar challenges.

Начало: 12.02.2026 Край: 01.05.2027 Възраст: от 18 г.

Nepal Possible NCT07370298

Набира участници

Innovative Approaches to Hypertension Management in High-Risk Emergency Department Populations

Asymptomatic Hypertension

This single-center, single-arm quasi-experimental study will assess the feasibility and acceptability of a community health worker (CHW)-led intervention to address social determinants of health (SDOH) among emergency department patients with hypertension. At enrollment, participants (N=15) will complete standardized SDOH surveys in REDCap, and CHWs will facilitate referrals to local community-based organizations that address identified social needs. With participant consent, the study will also include medical record review through EPIC and Healthix to evaluate healthcare utilization-including emergency department visits, hospitalizations, and outpatient encounters-during the one-year period before and after the index ED visit.

Начало: 12.02.2026 Край: 31.07.2026 Възраст: от 18 г.

United States Icahn School of Medicine at Mount Sinai NCT07539597

Набира участници Фаза 3

Efficacy And Safety Evaluation of Glepaglutide in Treatment of SBS

Short Bowel Syndrome

The purpose of the present Phase 3 trial is to confirm the efficacy and safety of glepaglutide 10 mg twice weekly in a patient population with SBS-IF and generate additional long-term safety data. Glepaglutide is the International Nonproprietary Name and United States Adopted Name (USAN) for ZP1848.

Начало: 11.02.2026 Край: 28.02.2032 Възраст: 18–90 г.

Austria, Denmark, France +9 Zealand Pharma NCT07197944

Набира участници Фаза 3

Ribociclib in Hormone Receptor-positive, HER2-negative Early Breast Cancer With Residual Disease After Neoadjuvant Chemotherapy

Breast Cancer

This is a multi-center, open-lable, prospective, randomized phase III clinical trial to investigate the efficacy and safety of adjuvant ribociclib combined with aromatase inhibitor in hormone receptor-positive, HER2-negative early breast cancer with residual disease after neoadjuvant chemotherapy

Начало: 10.02.2026 Край: 10.02.2031 Възраст: от 18 г.

China Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University NCT07400523

Набира участници

Effect of PRP in Donor Semen During Cryoprervation

Sperm Cryodamage

Sperm cryopreservation allows the preservation of sperm biological function for long periods of time for later use in assisted reproductive techniques (ART). However, the freezing and thawing process causes structural and functional damage to sperm, leading to decreased motility and vitality, a loss of plasma membrane integrity and even DNA damage. In recent years, various strategies have been studied to protect sperm from cryodamage, including the optimization of freezing processes, the design of freezing devices, and improved freezing media. One possible measure to mitigate the cryodamage suffered by sperm is the addition of PRP, or platelet-rich plasma, to the freezing medium. In previous studies, PRP components have been shown to have positive effects on semen quality, improving motility, viability, and plasma membrane integrity after cryopreservation. In light of these positive results, this study will evaluate the possibility of incorporating PRP into sperm cryopreservation media and its potential future benefits for patients and clinical outcomes. To this end, each semen sample after a previous spermiogram will be aliquoted, and 0%, 1%, 2%, and 5% PRP will be added to the cryopreservation medium according to the sperm group to which the belong. A spermiogram will be performed after cryopreservation to assess various semen quality parameters, including sperm count, motility, morphology, vitality, and chromatin dispersion. The data must be processed through statistical analysis to obtain results that allow determining, primarily, whether there is a beneficial effect on sperm quality after sperm motility and sperm during cryopreservation with the addition of PRP.

Начало: 10.02.2026 Край: 30.01.2028 Възраст: 18–35 г.

Spain Instituto Valenciano de Infertilidad, IVI Alicante NCT07504575

Набира участници

DSLT for Reducing Medication in Glaucoma

Primary Open Angle Glaucoma Ocular Hypertension

This is a prospective, single arm, open label study conducted at a single site to evaluate the efficacy of Direct Selective Laser Trabeculoplasty (DSLT) in reducing medication burden in patients with medically controlled ocular hypertension or primary open angle glaucoma. The study will assess the primary endpoint of reduction in medication count at 6 months compared to baseline. Secondary endpoints include IOP reduction compared to baseline (both percentage and absolute), complete success rate (no increase in IOP without medications), proportion of eyes needing medication at 6 months, and any secondary surgical interventions at 6 months post-DSLT. Participants will undergo DSLT with 120 shots, 400 µm spot size, and 1.8mJ fixed energy delivered at the limbus over 2.4 seconds. Follow-up visits will occur at 1 month, 3 months, and 6 months post-procedure, with IOP measured using a calibrated Goldmann tonometer.

Начало: 10.02.2026 Край: 26.01.2027

United States The Eye Institute of West Florida NCT07390890

Набира участници Фаза 2

A Study of Brenipatide in Adult Participants With Schizophrenia

Schizophrenia

The purpose of this study is to assess the efficacy and safety of brenipatide when administered with standard of care (SoC) compared to placebo plus SoC for treatment of schizophrenia. The trial is divided into three periods as follows: Screening period will last approximately 1 month, treatment period will last a maximum of 12 months, and the follow up period will last approximately 2 months. The length of time of your study participation may last up to approximately 15 months.

Начало: 10.02.2026 Край: 01.11.2027 Възраст: 18–55 г.

Argentina, Brazil, China +4 Eli Lilly and Company NCT07410507

Набира участници Фаза 1/2

First-Time-in-Human Study of GSK5471713 in Adults With mCRPC

Neoplasms, Prostate

This first-time-in-human study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, preliminary clinical activity, and establish the benefit/risk of GSK5471713 given as a monotherapy in mCRPC.

Начало: 10.02.2026 Край: 26.03.2030 Възраст: от 18 г.

Canada, Japan, United States GlaxoSmithKline NCT07332455

Набира участници

Self-balancing Personal Exoskeleton for SCI (WIP)

Spinal Cord Injuries Paraplegia and Tetraplegia

This study aims to demonstrate the safety and effectiveness of the personal exoskeleton in individuals with spinal cord injury (SCI).

Начало: 10.02.2026 Край: 30.04.2026 Възраст: от 18 г.

France Wandercraft NCT07536386

Набира участници

Relationships Between Nomophobia Levels and Perceived Stress, Body Image and Food Addiction Among University Students

Nomofobia Body Image Disturbance Body Image Body Image Disorder +3

The purpose of this study is to examine the effects of nomophobia levels on stress, food addiction, and body image among undergraduate students aged 18-30 at Bahçeşehir University, Faculty of Health Sciences. The primary questions it aims to answer are: * Is there a statistically significant relationship between nomophobia levels and perceived stress, food addiction, and body image among university students? * Is there a correlation between objective anthropometric data (body fat percentage, skeletal muscle mass) measured via Bioelectrical Impedance Analysis (BIA), waist/hip circumference measurements, and the individual's perceived body image?

Начало: 10.02.2026 Край: 01.05.2026 Възраст: 18–30 г.

Turkey (Türkiye) Bahçeşehir University NCT07518056

Набира участници Фаза 1

A Single Bolus, 12-hour Euglycemic Clamp Study of the Safety, Pharmacokinetics (PK) and Glucodynamics (GD) of Intraperitoneal (IP) Portal Insulin U-500

Type 1 Diabetes

The goal of this clinical trial is to assess the safety of a new U500 insulin formulation and to determine how rapidly it is absorbed and how long it takes to act when administered intraperitoneally. The trial will be conducted in people with Type 1 Diabetes. The main questions it aims to answer are: Is the drug safe and tolerable when administered intraperitoneally? How fast is it absorbed, and how long does it take to act? Researchers will compare the investigational product (PI-U500) with Humulin R U500 administered intraperitoneally and Lyumjev U100 administered subcutaneously. Participants will undergo a 12-hour clamp procedure in which their blood glucose will be maintained stable via glucose infusion at variable rates after a single intraperitoneal injection of the insulin formulation.

Начало: 10.02.2026 Край: 01.09.2026 Възраст: 18–60 г.

United States Portal Diabetes, Inc. NCT07341373

Набира участници Фаза 2

A Phase II Trial Comparing Immunotherapy Versus Capecitabine Maintenance After Chemo-chemoradiotherapy for High-risk Nasopharyngeal Carcinoma

Nasopharangeal Cancer

In this study, the investigators designed a randomized, open-label, phase II clinical trial for high-risk locally advanced nasopharyngeal carcinoma (T4 or N3 or EBV DNA ≥1500 copies/ml, AJCC 9th edition) that is sensitive to chemotherapy and PD-1 monoclonal antibody therapy. The trial compares sequential treatment with the TP regimen combined with PD-1 monoclonal antibody followed by concurrent chemoradiotherapy and PD-1 maintenance therapy versus capecitabine maintenance therapy. The aim is to provide high-quality clinical evidence for optimizing the treatment strategy for high-risk locally advanced nasopharyngeal carcinoma.

Начало: 10.02.2026 Край: 10.02.2033 Възраст: 18–70 г.

China Sun Yat-sen University NCT07392320

1 … 39 40 41 42 43 … 240